Create a diligence case, refine the thesis live with the AI agent, and export
an evidence-backed report or investment memo with key claims traced to dated sources.
Set up your case to begin
Top Biotech Users use Diligence for
Built from millions of conference abstracts, publications, trial records, and curated databases,
the Agent connects companies, assets, targets, indications, trials, mechanisms, and development stages
into a source-traced knowledge foundation for biotech diligence.
01 / 07
Every approved, clinical, investigational, and preclinical compound — carrying ChEMBL, DrugBank, PubChem, RxNorm, UNII, CAS, and InChIKey identifiers.
02 / 07
Gene and protein targets with druggability, genetic association, and expression — over 1.4M target mentions mined from the literature and trials.
03 / 07
Trials and readouts from every registry worldwide — 205,175 linked to a drug asset, in pursuit of the 100% coverage mandate.
04 / 07
First-class disease entities with ontology IDs, epidemiology, and unmet-need fields — 228,568 target↔indication validation edges.
05 / 07
The corpus that surfaces preclinical and academic competitors before they incorporate — plus 534,109 authors and PIs across 751,755 authorship links.
06 / 07
Sponsors, financials, and deals — 242,029 trial sponsorships and 120,681 collaboration edges, classified commercial vs. academic at ingestion.
07 / 07
Every fact above traces here — 4,037,721 EVIDENCED_BY links binding each claim to a dated source artifact with type, URL, and supporting span.
Proven results
Competing programs surfaced
across every global registry, patent office, and preprint server
100%
Median time to a first-draft memo
down from roughly three weeks of analyst work
4 hrs
Entities in the knowledge graph
drugs, targets, trials, companies, and evidence
1.6M+
Evidence artifacts behind every claim
each fact dated and traced to its source
1.3M+
Reduce diligence cost per deal
more theses evaluated per analyst, per week
>95%
